• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, February 8, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Acceptance of first non-animal method by China FDA anticipated

Bioengineer by Bioengineer
November 2, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

GAITHERSBURG, MD – November 2, 2016 – The Institute for In Vitro Sciences (IIVS) welcomes the news from China Food and Drug Administration (CFDA) officials that – for the first time in China – data from a non-animal test method will soon be recognized for safety evaluations of cosmetics.

The method, known as the 3T3 Phototoxicity assay, measures a chemical's potential to cause harm after exposure to light. The test has undergone formal validation internationally and has been incorporated into the OECD Test Guideline program (OECD TG #432). A subsequent inter-laboratory evaluation of the test was conducted in China with input from IIVS. Once the method is officially published by CFDA, it can be used to substantiate the safety of cosmetics, personal care products, and their ingredients.

"The anticipated publication by CFDA is an extremely important step for China" says Erin Hill, Co-Founder and President of IIVS. "It clearly demonstrates China's commitment to modernize their testing requirements and reduce their reliance on animal models".

IIVS and CFDA/National Institute for Food and Drug Control (NIFDC), which has regulatory authority over cosmetics in China, have been working together for several years under a Memorandum of Understanding (MOU) for scientific exchange around the use of non-animal (in vitro) methods for safety assessments. A key component of the MOU is an annual hands-on training provided by IIVS to national and provincial Institute for Food and Drug Control scientists. Over the past four years, approximately 400 regulatory scientists have been trained in methods such as phototoxicity, skin and eye irritation and skin sensitization. IIVS, together with NIFDC, is currently holding its 4th annual training at the laboratory facility of the Zhejiang Institute for Food and Drug control in Hangzhou, China.

IIVS Educational and Outreach programs are made possible by funding provided by its Industry Council for the Advancement of Regulatory Acceptance of Alternatives (ICARAA), other individual companies and animal protection organizations such as PETA.

About IIVS IIVS is a non-profit organization wholly dedicated to the promotion of rapid and innovative non-animal test methods Founded in 1997, IIVS is recognized as a leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programs coupled with educational and outreach initiatives have established IIVS as a global leader in the advancement of alternatives to animal testing. For more information, visit http://www.iivs.org.

###

Media Contact

Laura Henning
[email protected]
301-758-6078
@the_iivs

Home

Share12Tweet8Share2ShareShareShare2

Related Posts

Evaluating a Self-Care App for Chest Trauma Patients

February 8, 2026

Anesthesia Method’s Impact on Elderly Hip Fracture Recovery

February 8, 2026

Menopause Care: Insights from Workforce Review and Consultation

February 7, 2026

LRRK2R1627P Mutation Boosts Gut Inflammation, α-Synuclein

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13
  • Mapping Tertiary Lymphoid Structures for Kidney Cancer Biomarkers

    50 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Evaluating a Self-Care App for Chest Trauma Patients

Anesthesia Method’s Impact on Elderly Hip Fracture Recovery

Menopause Care: Insights from Workforce Review and Consultation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.